rev: January 23, 2002


Return (human cytokine index)

Human Cytokine/Growth Factor/Chemokines Sample Spec sheets (subject to change without notice):

Recombinant Human sVEGFR-3/FLT-4  (see also sVEGFR-3/fc chimera )
Recombinant Human sVEGFR-3/FLT-4

Description: Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy -terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT -4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774).

All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT -4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4. The Flt -4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stages of development. It is important for lymphangiogenesis.

Source:                                Insect cells

Molecular Weight:               120 kDa

Subunit:                                monomeric glycoprotein

Purity:                                  > 90%, by SDS-PAGE and visualised by silver stain

Endotoxin level:                  < 0.1 ng per mg of sVEGFR-3

Stabilizer:                           none

Buffer:                                 none

Formulation:                       lyophilized

Specific Activity: Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human sVEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.

Reconstitution: The lyophilised sVEGFR-3/FLT-4 is soluble in water and most aqueous buffers. The lyophilised sVEGFR-3/FLT-4 should be reconstituted in PBS or medium to a concentration not lower than 100 µg/ml.

Stability: Lyophilised samples are stable for greater than six months at -20°C to -70°C. Reconstituted sVEGFR-3/FLT -4 should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles!

Usage: sVEGFR-3/FLT -4 is offered for research use. Not for drug use. Not for human use.

Catalogue number:  RDI-S01-017     $440.00/vial  $375.00/vial 3+       Size: 50 µg

Range: 50-200 ng/ml

Literature: [Joukov et al., EMBO J 15 :290, 1996; Kukk et al., Development 122 :3829, 1996]

For In vitro research Use Only. Not for use in or on humans or animals or for diagnostics.  It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. We are not responsible for any patent infringements that might result with the use of or derivation of this product.

RDI Divison of Fitzgerald Industries Intl

34 Junction Square Drive

Concord MA 01742-3049


phone (978) 371-6446 or (800) 370-2222

fax     (978) 371-2266


Return (human cytokine index)

all rights reserved by any/all copyright holders?